Lantheus to buy radiopharma CDMO and diagnostic assets for $250M upfront

Anna Brown

News Reporter

In its latest move to expand its portfolio, Lantheus Holdings is spending $250 million upfront to buy radiopharma CDMO and diagnostics company Evergreen Theragnostics, which …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lantheus to buy radiopharma CDMO and diagnostic assets for $250M upfront

Anna Brown

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

RFK blog: Kennedy survives Senate grilling, with no bombshells to derail HHS confirmation

Trump administration makes first comments on how it will run IRA drug negotiations

8VC, a tech and life sciences VC firm behind Altos Labs, eyes $1B fund

23andMe weighs a sale as cash dwindles

One February FDA adcomm meeting is delayed, another canceled

Why the premier recruitment agency in the world is giving up recruiting, and sponsors should, too

Lan­theus to buy ra­dio­phar­ma CD­MO and di­ag­nos­tic as­sets for $250M up­front

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Lantheus to buy radiopharma CDMO and diagnostic assets for $250M upfront